ArriVent BioPharma, Inc.

A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.

AVBP | NDAQ

Overview

Corporate Details

ISIN(s):: US04272N1028
LEI:
Country:: United States of America
Address:: 18 CAMPUS BLVD., NEWTOWN SQUARE
Website:: https://arrivent.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to identifying, developing, and commercializing differentiated medicines for patients with difficult-to-treat diseases, with an initial focus on oncology. The company's strategy centers on forging strategic partnerships to in-license and accelerate the global development of promising drug candidates. Its pipeline is led by its lead development candidate, firmonertinib, an investigational cancer therapeutic, and includes other novel oncology treatments such as next-generation antibody-drug conjugates. ArriVent leverages its team's extensive drug development and regulatory expertise to advance its portfolio and address significant unmet medical needs for global patient populations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ArriVent BioPharma, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ArriVent BioPharma, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for ArriVent BioPharma, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
HELLENIC DYNAMICS PLC Cultivates and supplies THC-dominant medical cannabis for the European pharmaceutical market.	United Kingdom	HELD
HEMOGENYX PHARMACEUTICALS PLC Develops CAR-T therapies for blood cancers, autoimmune disorders, and viral infections.	United Kingdom	HEMO
HEM Pharma Inc. Microbiome biotech using analysis for personalized probiotics, LBPs, and full CDMO services.	South Korea	376270
Hemp Health Spolka Akcyjna A vertically integrated supplier of medical cannabis raw material for the Polish market.	Poland	HMP
Herantis Pharma Oyj Developing disease-modifying therapies for neurodegenerative conditions like Parkinson's disease.	Finland	HRTIS
HERON THERAPEUTICS, INC. /DE/ Develops and commercializes therapies for acute care and oncology to manage pain and nausea.	United States of America	HRTX
HIGH TECH PHARM CO.,LTD. Global manufacturer of carbapenem antibiotic APIs for regulated markets.	South Korea	106190
HIKMA Pharmaceuticals PLC Develops & markets affordable generic & specialty medicines for markets in NA, MENA, & Europe.	United Kingdom	HIK
HISAMITSU PHARMACEUTICAL CO.,INC. A global leader in transdermal drug delivery systems for OTC and prescription pain relief.	Japan	4530
HLB Genex, Inc. Develops custom enzymes & microbiome solutions for diagnostics, nutrition, and cosmetic markets.	South Korea	187420